Neurology Articles

Neurology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

McCormack AI et al. - MGMT expression as assessed by immunohistochemistry may predict response to temozolomide therapy in patients with aggressive pituitary tumours. MGMT promoter methylation is likely to explain low MGMT expression in some, but not all, pituitary tumours.

Related Articles

The natural history of surgically treated but radiotherapy-naive nonfunctioning pituitary adenomas
Clinical Endocrinology, 10/15/09    Relevance Score: 66%

Signalling Pathway Alterations in Pituitary Adenomas: Involvement of Gsalpha, cAMP and Mitogen-Activated Protein Kinases
Journal of Neuroendocrinology, 11/03/09    Relevance Score: 65%

Acromegaly associated with gangliocytoma
Irish Journal of Medical Science, 10/01/09    Relevance Score: 65%

Optic nerve haemangioblastoma mimicking a planum sphenoidale meningioma
British Journal of Neurosurgery, 10/01/09    Relevance Score: 64%

The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer
Acta Oncologica, 11/02/09    Relevance Score: 48%

Today in Neuroendocrinology...keeping you current

Evaluation of antioxidant systems in pituitary-adrenal axis diseases
Pituitary, 12/18/09

A heritable predisposition to pituitary tumors
Pituitary, 12/18/09

The risk for breast cancer is not evidently increased in women with hyperprolactinemia
Pituitary, 12/18/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address